Impact Factor 2.349 | CiteScore 2.20
More on impact ›

Correction ARTICLE

Front. Pediatr., 13 November 2019 | https://doi.org/10.3389/fped.2019.00466

Corrigendum: Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention

  • 1INSERM U1170, Equipe Labellisée Ligue Contre le Cancer, Gustave Roussy Institute, Université Paris Diderot, Université Paris-Sud, Villejuif, France
  • 2Department of Biomedicine, University Children's Hospital Beider Basel (UKBB), University of Basel, Basel, Switzerland

A Corrigendum on
Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention

by Mercher, T., and Schwaller, J. (2019). Front. Pediatr. 7:401. doi: 10.3389/fped.2019.00401

In the original article, there was a mistake in the legend for Figure 5 as published.

In the legend of Figure 5, it states “[adapted from Carmichael et al. (90)]” instead of “[adapted from Rodriguez-Fraticelli et al. (95)]”. The correct legend appears below.

Figure 5 Hematopoietic developmental stage and hierarchy-dependent susceptibility for transformation by AML-associated fusion oncogenes. (A) Increasing evidence suggests that pediatric AML-associated oncogenes have a particular window of opportunity during development to transform hematopoietic cells. GATA1s and Trisomy 21 have been shown to induce stage-specific alteration of fetal hematopoiesis (86). For KMT2A–AFF1+ leukemia, the fusion was found not only in hematopoietic precursors but also in BM stroma cells (83), suggesting that the fusion might target a very early precursor cell that maintain some mesenchymal properties. (B) Differential susceptibility of cells of the hematopoietic hierarchy for transformation by fusion oncogenes associated with pediatric AML [adapted from Rodriguez-Fraticelli et al. (95)]. Together, these observations suggest that both the developmental stage and the type of cell in the hematopoietic hierarchy in which a genetic alteration occurs determines whether a leukemia will develop and the associated disease phenotype and aggressiveness.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: pediatric AML, genomic landscape, mouse models, fusion oncogene, therapeutic targeting, UKBB

Citation: Mercher T and Schwaller J (2019) Corrigendum: Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Front. Pediatr. 7:466. doi: 10.3389/fped.2019.00466

Received: 23 October 2019; Accepted: 24 October 2019;
Published: 13 November 2019.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2019 Mercher and Schwaller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Thomas Mercher, thomas.mercher@inserm.fr; Juerg Schwaller, j.schwaller@unibas.ch